First human trial of ELP-02 aims to halt rare nerve disease
Disease control
Not yet recruiting
This study tests a single injection of a new drug, ELP-02, given into the spine for people aged 3 to 20 with a rare genetic nerve disease called CMT4J. The main goal is to see if the drug is safe and if it can slow or stop muscle damage. Only 8 participants will be enrolled in th…
Phase: PHASE1, PHASE2 • Sponsor: Elpida Therapeutics SPC • Aim: Disease control
Last updated May 11, 2026 20:50 UTC